Market Trends & Consumer Behavior - Cannabis is becoming more accepted and normalized, even finding its way onto holiday dinner tables [1][2] - Alcohol consumption is at its lowest level in decades, with over half of respondents substituting cannabis for alcohol at least weekly [2][3] - The day before Thanksgiving is the second biggest sales day for the U S legal cannabis industry [4] - A cultural shift is making its way into some holiday dinners [8] Industry Growth & Financials - The U S legal cannabis industry was valued at just over $30 billion last year [4] - The cannabis market is forecasted to grow 4% this year to $31 6 billion [4] - The market is expected to reach $39 1 billion by 2029 [5] Legal & Regulatory Landscape - Despite state legalization, cannabis is still considered a Schedule one drug at the federal level, limiting access to banking investment and broader legitimacy [7] - Uncertainty at the federal level remains a significant hurdle for the industry [7][8]

Core Points - Canopy Growth Corporation will release its financial results for the second quarter of fiscal year 2026 on November 7, 2025, before the markets open [1] - Following the financial results release, an audio webcast will be hosted by the CEO and CFO on the same day at 10 AM ET [2] - Canopy Growth is a leading cannabis company focused on improving lives through innovative cannabis products and services [3][5] Company Overview - Canopy Growth offers a range of products from owned and licensed brands, including Tweed, 7ACRES, DOJA, and Deep Space, as well as vaporization devices by Storz & Bickel [3] - The company serves medical cannabis patients globally, with operations primarily in Canada, Europe, and Australia [3] - Canopy Growth has a non-controlling interest in Canopy USA, LLC, which includes a portfolio of cannabis-related businesses across the U.S. [4] Recent Developments - The DOJA facility in Kelowna, British Columbia, is now dedicated exclusively to medical cannabis cultivation, supporting the Spectrum Therapeutics portfolio in Canada [8] - Canopy Growth recently held its Annual General and Special Meeting of Shareholders, which was adjourned due to a lack of quorum and reconvened on October 10, 2025 [9]

Industry Focus - The cannabis and mushroom industries are converging to create billion-dollar medications [1] Company Strategy - Companies in the CBD sector are developing plans to produce medications from cannabis and mushrooms [1]

Core Insights - Tilray Brands Inc. reported better-than-expected first-quarter 2026 earnings, achieving break-even compared to a consensus loss of 2 cents per share, with adjusted net income of $3.9 million versus an adjusted net loss of $(6.1) million [1] - Adjusted EBITDA increased by 9% year over year to $10.2 million, up from $9.3 million [1] Revenue Performance - Net revenue rose by 5% to $209.5 million, exceeding the consensus estimate of $204.55 million [2] - Cannabis net revenue increased by 5% to $64.5 million, compared to $61.2 million [2] - Beverage net revenue was slightly down at $55.7 million compared to $56.0 million [2] - Wellness net revenue increased to $15.2 million from $14.8 million [2] - Distribution net revenue grew to $74.0 million from $68.1 million [2] Margin and Debt Management - Gross margin contracted from 30% to 27% [3] - The company reduced its debt by $7.7 million, improving its balance sheet, with a net debt to trailing twelve months adjusted EBITDA ratio of 0.07x [4] - Tilray holds a cash balance of $264.8 million, providing flexibility for strategic opportunities [4] Market Activity - Tilray's stock surged by 29.36%, reaching $2.23 [5] - The company announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products [5]

Regulatory Landscape - The 2018 Farm Bill legalized hemp-derived CBD [3] - Potential reclassification of cannabis to schedule three could reduce criminal penalties and lower costs for companies [3] Market Implications - Reclassification could lead to more affordable CBD products for consumers [3] - Increased research into medical uses of cannabis may occur [3] Potential Benefits - Hemp-derived CBD may improve the quality of life for older adults [2] - CBD could be an alternative to expensive prescription drugs [2]

And a post last night on Truth Social, President Trump shared a video highlighting the health benefits of hemp hemp derived cannabid oil or CBD. Now, Tillray, Canopy Growth, Aurora, all jumping double digits. The video said it could quote, "Revolutionize senior health care, serving as a alternative to costly prescription drugs." Of course, another area of the president's focus.Now, this isn't Trump's first move in cannabis, though. Back in the 2018 Farm Bill, hemp derived products like CBD were legalized. A ...

Cannabis Industry & Policy - President Trump shared a video highlighting the health benefits of hemp-derived CBD, potentially revolutionizing senior healthcare as an alternative to costly prescription drugs [1][2] - The 2018 Farm Bill legalized hemp-derived products like CBD [3] - Trump hinted at reclassifying cannabis from a Schedule 1 drug to a less dangerous Schedule 3, alongside steroids and Tylenol with codeine [3] - Reclassification would ease criminal penalties, lift tax burdens on companies, and open the pathway to more medical research [4] - New HHS standards for "accepted medical use" acknowledge widespread physician use and some credible scientific support, rather than demanding full FDA level clinical trial evidence [4] Market Reaction & Stock Performance - Tilray, Canopy Growth, and Aurora are all jumping double digits [2] - The cannabis sector has been volatile, with some stocks halving in value this year and others gaining over 30% [5] - Investors are reacting positively to the news regarding potential reclassification [5] Regulatory Process & Future Outlook - The decision to reclassify cannabis needs to come from the administration [6] - The previous administration did a lot of the work in terms of reclassification, putting forward the DEA's recommendation and opening it for public comment [6] - The current administration has the power to expedite the reclassification process [6] - Rescheduling could move cannabis stocks forward [7]

Market Trends - With federal legalization stalled in the US, cannabis companies are exploring opportunities in the European market [1] Industry Dynamics - Cannabis companies are finding a new "Green Rush" in Europe [1]

Thailand’s cannabis industry is hoping for a revival under new Prime Minister Anutin Charnvirakul https://t.co/MDZazmV37S ...

Check out Forbes' fourth-annual Cannabis 42.0 list to see the pot pioneers blazing a path forward in 2025. https://t.co/kmNewSzzXn https://t.co/0yv1uYy1mE ...